AURA
Aura Biosciences Inc
NASDAQ · Biotechnology
$5.60
+0.24 (+4.48%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| EPS | — | — | — |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| Rev Growth | +9.8% | +0.1% | +6.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 177.56M | 162.16M | 164.48M |
| Total Equity | 163.32M | 159.36M | 172.59M |
| D/E Ratio | 1.09 | 1.02 | 0.95 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |